The Potential of Liquid Biopsy in Cancer Diagnosis and Monitoring of Treatment Response |Biomedgrid

Liquid biopsy, a non-invasive method of analyzing cancer biomarkers in blood and other bodily fluids, has emerged as a promising approach for cancer diagnosis and monitoring of treatment response. The three main types of liquid biopsy include Circulating Tumor Cells (CTCs), Cell-Free DNA (cfDNA), and Extracellular Vesicles (EVs). Liquid biopsy offers several advantages over traditional tissue biopsy, including minimal invasiveness, ability to monitor disease progression in real-time, and potential for early cancer detection. However, challenges and limitations associated with liquid biopsy remain, such as the need for standardized protocols and assays, and the potential for false positives and negatives. Despite these challenges, liquid biopsy has shown great promise in clinical applications, such as monitoring of treatment response and resistance, and the identification of actionable mutations for targeted therapy. In conclusion, liquid biopsy holds great potential for improving cancer diagnosis and management, and ongoing research efforts will continue to refine and expand its clinical applications.